Stem Cell Therapeutics, Medicon start dosing in phase 1 trial of NTx-265 for stroke

New York, Nov. 29 - Stem Cell Therapeutics Corp. said Medicon A/S has begun dosing of patients in the phase 1 clinical study of NTx-265, Stem Cell Therapeutics' program to treat stroke.

The phase 1 trial is designed to characterize the pharmacokinetic profile of two currently marketed drugs, identified by Stem Cell Therapeutics as effective in non-clinical models of stroke.

Patients will be dosed in two groups staggered by about two weeks.

The trial is expected to run for eight weeks.

Medicon, a Birkerod, Denmark, drug development organization, is carrying out the study for Stem Cell Therapeutics.

Stem Cell Therapeutics also has a phase 2 trial planned to evaluate safety and efficacy of its NTx-265 therapy in stroke patients.

The company said NTx-265 has been demonstrated to increase the number of innate adult stem cells that grow in place when this therapeutic approach is applied to test animals.

"Dosing our first patient represents a turning point in the evolution of Stem Cell Therapeutics Corp. from a pre-clinical research and development company into a company with the capacity to rapidly graduate promising stem cell technologies through clinical safety and efficacy testing in man," said Dr. Alan Moore, chief clinical and regulatory officer of Stem Cell Therapeutics, in a news release.

Stem Cell Therapeutics is a Calgary, Alta., biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.